651780-02-8

Basic information

• Product Name: TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE;1-Boc-5-bromoindazole;5-Bromo-1H-indazole, N1-BOC protected 90%;5-Bromo-1H-indazole, N1-BOC;1H-Indazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester;5-broMo-3-tert-butyl-1H-indazole-1-carboxylate;1-(tert-Butoxycarbonyl)-5-bromoindazole;1-Boc-5-bromo-1H-indazole
• CAS NO: 651780-02-8
• Molecular Formula: C₁₂H₁₃BrN₂O₂
• Molecular Weight: 297.15
• Mol File: 651780-02-8.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 377℃
• Flash Point: 182℃
• Appearance: /
• Density: 1.46
• Vapor Pressure: 6.77E-06mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: 2-8°C
• PKA: -2.63±0.30(Predicted)
• CAS DataBase Reference: TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE(651780-02-8)
• EPA Substance Registry System: TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE(651780-02-8)

Safety Data

• Hazardous Substances Data: 651780-02-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl 5-bromo-1H-indazole-1-carboxylate is a chemical compound that contains a tert-butyl group, a bromine atom, and an indazole ring with a carboxylate functional group. TERT-BUTYL 5-BROMO-1H-INDAZOLE-1-CARBOXYLATE has potential applications in organic synthesis and pharmaceutical research due to its unique structure and functional groups, which may contribute to its potential reactivity and biological activity. It could be used as a building block in the synthesis of various organic compounds or as a precursor in the production of pharmaceuticals and agrochemicals. Its specific properties and potential uses may make it of interest to researchers and chemists in various fields.

InChI:InChI=1/C12H13BrN2O2/c1-12(2,3)17-11(16)15-10-5-4-9(13)6-8(10)7-14-15/h4-7H,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 53857-57-1 5-bromo-1H-indazole 

Downstream Products

• 864771-44-8 1,1-dimethylethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate 
• 906003-88-1 5-(4-fluoro-3-formylphenyl)-indazole-1-carboxylic acid tert-butyl ester 
• 877264-73-8 tert-butyl 5-acetyl-1H-indazole-1-carboxylate 
• 1093302-40-9 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole 
• 1093302-48-7 5-[1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-49-8 5-[1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-50-1 5-[1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-45-4 5-[1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-46-5 5-[1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-47-6 5-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-42-1 5-[1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-68-1 5-[1-(2,3-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-70-5 5-[1-(2,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 
• 1093302-71-6 5-[1-(3,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole 

Relevant articles and documents

PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation

Based on indole scaffold, a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, namely FD223, was developed by the bioisosteric replacement drug discovery approach and studied for the treatment of acute myeloid leukemia (AML). In vitro

GDF-8 INHIBITORS

Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.